Nitroxyl Hybrids with Curcumin and Stilbene Scaffolds Display Potent Antioxidant Activity, Remodel the Amyloid Beta Oligomer, and Reverse Amyloid Beta-Induced Cytotoxicity
- PMID: 39594552
- PMCID: PMC11591036
- DOI: 10.3390/antiox13111411
Nitroxyl Hybrids with Curcumin and Stilbene Scaffolds Display Potent Antioxidant Activity, Remodel the Amyloid Beta Oligomer, and Reverse Amyloid Beta-Induced Cytotoxicity
Abstract
The disorder and heterogeneity of low-molecular-weight amyloid-beta oligomers (AβOs) underlie their participation in multiple modes of cellular dysfunction associated with the etiology of Alzheimer's disease (AD). The lack of specified conformational states in these species complicates efforts to select or design small molecules to targeting discrete pathogenic states. Furthermore, targeting AβOs alone may be therapeutically insufficient, as AD progresses as a multifactorial, self-amplifying cascade. To address these challenges, we have screened the activity of seven new candidates that serve as Paramagnetic Amyloid Ligand (PAL) candidates. PALs are bifunctional small molecules that both remodel the AβO structure and localize a potent antioxidant that mimics the activity of SOD within live cells. The candidates are built from either a stilbene or curcumin scaffold with nitroxyl moiety to serve as catalytic antioxidants. Measurements of PAL AβO binding and remolding along with assessments of bioactivity allow for the extraction of useful SAR information from screening data. One candidate (HO-4450; PMT-307), with a six-membered nitroxyl ring attached to a stilbene ring, displays the highest potency in protecting against cell-derived Aβ. A preliminary low-dose evaluation in AD model mice provides evidence of modest treatment effects by HO-4450. The results for the curcumin PALs demonstrate that the retention of the native curcumin phenolic groups is advantageous to the design of the hybrid PAL candidates. Finally, the PAL remodeling of AβO secondary structures shows a reasonable correlation between a candidate's bioactivity and its ability to reduce the fraction of antiparallel β-strand.
Keywords: Alzheimer’s disease; Aβ oligomer; EPR; amyloid beta peptide; antioxidant; bifunctional drug; electron paramagnetic resonance spectroscopy; nitroxide; oxidative stress; protein misfolding.
Conflict of interest statement
Authors J.S. and J.C.V. were employed by the company Paramag, Inc. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Figures









Similar articles
-
Novel Stilbene-Nitroxyl Hybrid Compounds Display Discrete Modulation of Amyloid Beta Toxicity and Structure.Front Chem. 2022 May 26;10:896386. doi: 10.3389/fchem.2022.896386. eCollection 2022. Front Chem. 2022. PMID: 35720993 Free PMC article.
-
Natural products targeting amyloid-β oligomer neurotoxicity in Alzheimer's disease.Eur J Med Chem. 2024 Oct 5;276:116684. doi: 10.1016/j.ejmech.2024.116684. Epub 2024 Jul 14. Eur J Med Chem. 2024. PMID: 39032401 Review.
-
Amyloid β oligomers in Alzheimer's disease pathogenesis, treatment, and diagnosis.Acta Neuropathol. 2015 Feb;129(2):183-206. doi: 10.1007/s00401-015-1386-3. Epub 2015 Jan 22. Acta Neuropathol. 2015. PMID: 25604547 Free PMC article. Review.
-
ACU193: An Immunotherapeutic Poised to Test the Amyloid β Oligomer Hypothesis of Alzheimer's Disease.Front Neurosci. 2022 Apr 26;16:848215. doi: 10.3389/fnins.2022.848215. eCollection 2022. Front Neurosci. 2022. PMID: 35557606 Free PMC article. Review.
-
Protection against Amyloid-β Oligomer Neurotoxicity by Small Molecules with Antioxidative Properties: Potential for the Prevention of Alzheimer's Disease Dementia.Antioxidants (Basel). 2022 Jan 7;11(1):132. doi: 10.3390/antiox11010132. Antioxidants (Basel). 2022. PMID: 35052635 Free PMC article. Review.
References
-
- Sperling R.A., Donohue M.C., Raman R., Sun C.K., Yaari R., Holdridge K., Siemers E., Johnson K.A., Aisen P.S., A4 Study Team Association of Factors With Elevated Amyloid Burden in Clinically Normal Older Individuals. JAMA Neurol. 2020;77:735–745. doi: 10.1001/jamaneurol.2020.0387. - DOI - PMC - PubMed
Grants and funding
LinkOut - more resources
Full Text Sources
Molecular Biology Databases
Miscellaneous